4 ms·
The problem is that this option is to buy AZ's current vaccine that have a high probability of being ineffective in 18 months. EU is not saying that it won't bu
by polack 5y ago
The problem is that this option is to buy AZ's current vaccine that have a high probability of being ineffective in 18 months. EU is not saying that it won't buy from AZ, but as of now it's not well spent money to buy their current one to be delivered in 18 months. By then all companies will have new better vaccines and the EU would have to fork up a shitload of money on the new AZ vaccine and just write the old of as another loss while the AZ execs get another fat bonus paid by the EU citizens.
- Hallucinaut 5y agoIsn't AZ selling the vaccine at cost? Won't AZ also have the opportunity to improve their vaccine (or delivery protocol)? Won't more data be available in one year with which to make these decisions?
- JamisonM 5y agoRegardless of the margins involved, I think it is improbable that AZ would want to produce an obsolete vaccine when those facilities could be producing a better one if they have something ready to go. Its not like everyone involved here is a sociopath, they can put the money down now and renegotiate for a mutually beneficial change to the contract.
- JamisonM 5y ago> The problem is that this option is to buy AZ's current vaccine that have a high probability of being ineffective in 18 months. I doubt that is a "high probability" occurrence. If it does occur and AZ makes a lot of money, I don't care. The EU has many shitloads of money to spend, spread out your bets, go to town, reward every vaccine producer with huge profits, that's what we want, we want all of the companies that bet big on developing products - successful or unsuccessful - to make money off this thing. That way if it happens again they won't be shy about giving it another go!